欧林生物: 成都欧林生物科技股份有限公司关于以简易程序向特定对象发行A股股票摊薄即期回报与采取填补措施及相关主体承诺（修订稿）的公告

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is issuing A-shares to specific investors, which may dilute immediate returns, and the company has proposed measures to mitigate this impact [1][5]. Financial Impact Analysis - The company analyzed the impact of the stock issuance on key financial metrics under three scenarios for 2025 net profit compared to 2024: - Scenario 1: 10% increase in net profit results in net profit of 22.83 million yuan and basic earnings per share (EPS) of 0.0558 yuan [3]. - Scenario 2: Net profit remains unchanged at 20.76 million yuan, leading to basic EPS of 0.0507 yuan [4]. - Scenario 3: 10% decrease in net profit results in net profit of 18.68 million yuan and basic EPS of 0.0457 yuan [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for the "Vaccine R&D Production Base Technology Renovation Project," which aligns with the company's core business and development strategy [5][6]. Company’s Resource and Capability Assessment - The company has a stable management team with extensive experience in the biopharmaceutical industry and is committed to continuous talent development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccines [7][8]. Measures to Mitigate Dilution of Immediate Returns - The company will maintain stable growth in its main business and accelerate the investment progress of the fundraising projects to enhance profitability [9]. - It will strengthen fundraising management to ensure compliance and effective use of raised funds [11]. - The company plans to improve its profit distribution policy to optimize investor returns [12][13]. Commitments from Major Stakeholders - The controlling shareholders and actual controllers have committed to ensuring the fulfillment of measures to mitigate the dilution of immediate returns [14][15]. - The board of directors and senior management have also made commitments to protect company interests and ensure compliance with regulations [15][16].